Bio-Path Holdings ( (BPTH) ) has issued an announcement.
On March 18, 2025, Bio-Path Holdings announced promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients. The studies showed that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models. This progress suggests a new application for BP1001-A beyond current weight loss drugs, potentially offering a novel therapeutic option for reducing glucose levels in patients with Type 2 diabetes. Bio-Path plans to advance these studies and file for regulatory designations to accelerate approval, with a final pre-clinical mouse model study expected in the first half of 2025 and an IND filing by year-end.
More about Bio-Path Holdings
Bio-Path Holdings, Inc. is a biotechnology company that develops a portfolio of targeted nucleic acid cancer and obesity drugs using its proprietary DNAbilize® liposomal delivery and antisense technology. The company’s lead product candidate, prexigebersen (BP1001), is in a Phase 2 study for blood cancers, while BP1001-A, a modification of prexigebersen, is being evaluated for solid tumors and as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients.
YTD Price Performance: -86.52%
Average Trading Volume: 594,270
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.29M
For detailed information about BPTH stock, go to TipRanks’ Stock Analysis page.
